Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease
Status:
Recruiting
Trial end date:
2023-12-30
Target enrollment:
Participant gender:
Summary
In clinical trials of preclinical pharmacodynamic studies, Flos Gossypii Flavonoids Tablet
has been proved to significantly improve the learning and memory ability of Alzheimer's
disease model. Phase I clinical tolerance test is to observe the human body's tolerance to
Flos Gossypii Flavonoids Tablet, and provide a basis for the formulation of safe and
reasonable dosing regimens for phase II clinical trials. Therefore, a Phase II clinical trial
is now being conducted to explore the efficacy and safety of the Flos Gossypii Flavonoids
Tablet in the treatment of mild to moderate Alzheimer's disease (marinus sea deficiency/brain
collateral stasis syndrome). In this study, the researchers will use a multicenter,
randomized, double-blind, placebo-controlled parallel method to recruit AD patients to
confirm the efficacy and safety of Flos Gossypii Flavonoids Tablet. Confirmation of drug
efficacy will be observed through changes in AD patients' general cognitive and different
cognitive domain functions, daily living activities, and symptom severities.